Cargando…

New challenges in the use of nanomedicine in cancer therapy

Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasool, Mahmood, Malik, Arif, Waquar, Sulayman, Arooj, Mahwish, Zahid, Sara, Asif, Muhammad, Shaheen, Sumaira, Hussain, Abrar, Ullah, Hamid, Gan, Siew Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805951/
https://www.ncbi.nlm.nih.gov/pubmed/34856849
http://dx.doi.org/10.1080/21655979.2021.2012907
_version_ 1784643336764653568
author Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Arooj, Mahwish
Zahid, Sara
Asif, Muhammad
Shaheen, Sumaira
Hussain, Abrar
Ullah, Hamid
Gan, Siew Hua
author_facet Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Arooj, Mahwish
Zahid, Sara
Asif, Muhammad
Shaheen, Sumaira
Hussain, Abrar
Ullah, Hamid
Gan, Siew Hua
author_sort Rasool, Mahmood
collection PubMed
description Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additionally, the use of minute amounts of drugs can lead to cost savings. In addition, nanotechnology is effectively applied in the preparation of such drugs as they are in nm sizes, considered one of the earliest cutoff values for the production of products utilized in nanotechnology. Early concepts described gold nanoshells as one of the successful therapies for cancer and associated diseases where the benefits of nanomedicine include effective active or passive targeting. Common medicines are degraded at a higher rate, whereas the degradation of macromolecules is time-consuming. All of the discussed properties are responsible for executing the physiological behaviors occurring at the following scale, depending on the geometry. Finally, large nanomaterials based on organic, lipid, inorganic, protein, and synthetic polymers have also been utilized to develop novel cancer cures.
format Online
Article
Text
id pubmed-8805951
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88059512022-02-02 New challenges in the use of nanomedicine in cancer therapy Rasool, Mahmood Malik, Arif Waquar, Sulayman Arooj, Mahwish Zahid, Sara Asif, Muhammad Shaheen, Sumaira Hussain, Abrar Ullah, Hamid Gan, Siew Hua Bioengineered Review Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additionally, the use of minute amounts of drugs can lead to cost savings. In addition, nanotechnology is effectively applied in the preparation of such drugs as they are in nm sizes, considered one of the earliest cutoff values for the production of products utilized in nanotechnology. Early concepts described gold nanoshells as one of the successful therapies for cancer and associated diseases where the benefits of nanomedicine include effective active or passive targeting. Common medicines are degraded at a higher rate, whereas the degradation of macromolecules is time-consuming. All of the discussed properties are responsible for executing the physiological behaviors occurring at the following scale, depending on the geometry. Finally, large nanomaterials based on organic, lipid, inorganic, protein, and synthetic polymers have also been utilized to develop novel cancer cures. Taylor & Francis 2022-01-04 /pmc/articles/PMC8805951/ /pubmed/34856849 http://dx.doi.org/10.1080/21655979.2021.2012907 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Rasool, Mahmood
Malik, Arif
Waquar, Sulayman
Arooj, Mahwish
Zahid, Sara
Asif, Muhammad
Shaheen, Sumaira
Hussain, Abrar
Ullah, Hamid
Gan, Siew Hua
New challenges in the use of nanomedicine in cancer therapy
title New challenges in the use of nanomedicine in cancer therapy
title_full New challenges in the use of nanomedicine in cancer therapy
title_fullStr New challenges in the use of nanomedicine in cancer therapy
title_full_unstemmed New challenges in the use of nanomedicine in cancer therapy
title_short New challenges in the use of nanomedicine in cancer therapy
title_sort new challenges in the use of nanomedicine in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805951/
https://www.ncbi.nlm.nih.gov/pubmed/34856849
http://dx.doi.org/10.1080/21655979.2021.2012907
work_keys_str_mv AT rasoolmahmood newchallengesintheuseofnanomedicineincancertherapy
AT malikarif newchallengesintheuseofnanomedicineincancertherapy
AT waquarsulayman newchallengesintheuseofnanomedicineincancertherapy
AT aroojmahwish newchallengesintheuseofnanomedicineincancertherapy
AT zahidsara newchallengesintheuseofnanomedicineincancertherapy
AT asifmuhammad newchallengesintheuseofnanomedicineincancertherapy
AT shaheensumaira newchallengesintheuseofnanomedicineincancertherapy
AT hussainabrar newchallengesintheuseofnanomedicineincancertherapy
AT ullahhamid newchallengesintheuseofnanomedicineincancertherapy
AT gansiewhua newchallengesintheuseofnanomedicineincancertherapy